PMC:2792620 / 11870-12825 JSONTXT

{"project":"2_test","denotations":[{"id":"20040958-12904152-47224443","span":{"begin":294,"end":296},"obj":"12904152"},{"id":"20040958-11901288-47224444","span":{"begin":687,"end":689},"obj":"11901288"},{"id":"20040958-9932994-47224445","span":{"begin":880,"end":882},"obj":"9932994"},{"id":"20040958-10926979-47224445","span":{"begin":880,"end":882},"obj":"10926979"},{"id":"T70089","span":{"begin":294,"end":296},"obj":"12904152"},{"id":"T91594","span":{"begin":687,"end":689},"obj":"11901288"},{"id":"T54693","span":{"begin":880,"end":882},"obj":"9932994"},{"id":"T16412","span":{"begin":880,"end":882},"obj":"10926979"}],"text":"Brimonidine\nBrimonidine is the a-2 agonist of choice in glaucoma treatment, which acts by decreasing the aqueous humor secretion and increasing the uveoscleral outflow. It does not cross the blood-brain barrier and is 30 times more selective for the a-2-adrenergic receptor than apraclonidine.[21] Brimonidine is believed to have neuroprotective effect, which is an important parameter of glaucoma pathogenesis.\nBrimonidine is used as a first-line therapy in patients who have contraindications to β blockers. In a double-masked, placebo-controlled trial, brimonidine was effective in reducing the IOP in patients with elevated IOP. Its efficacy was equivalent to that of apraclonidine.[22] Due to high selective action on a-2 adrenoceptor agonist activity, the IOP-lowering ability of brimonidine may be comparable with that of timolol and dorzolamide and superior to betaxolol.[23–25] Brimonidine is available as 0.2 and 0.5%, to be applied twice daily."}